Skip to main content

Houston Organizations Gaining Recognition for Innovation in Life Sciences

Published Jul 11, 2022 by Brina Morales

UH Medtech Robotic Arm

Houston is known for its world-class institutions and professional talent in the health care and life sciences industries, so it comes as no surprise that healthcare systems, academic institutions and medtech startups are being recognized for their innovations. 

Here are just a few examples: 

Brain-Controlled Robotic Arm for Stroke Patients

The University of Houston recently made news with its creation of a robotic arm that can be controlled by a patient’s brainwaves – it’s considered a gamechanger for stroke patients. According to UH, engineering professor Jose Luis Contreras-Vidal and his team developed the portable brain-computer interface (BCI) exoskeleton to restore upper limb function. Contreras-Vidal’s innovation differs from similar technologies because the brain-controlled robotic arm doesn’t require surgery and is available to a patient both at home and in a clinic. Most neuro technologies are limited to a lab or clinic and are expensive and hard to operate, according to UH.

 

Brain-controlled robotic arm can be used by stroke patients to recover the use of a limb. (Courtesy: Catalina Rodriguez/University of Houston)

“The broader impact and commercial potential of this project is to advance national health by accelerating development, efficacy and use of brain-controlled robotic rehabilitation after stroke by capitalizing on the benefits of non-invasive brain interfaces that extract information about the patient’s motor intent and the real-time assessment of impairment and recovery of motor function," said Contreras-Vidal.

Robotic-assisted Heart Surgery

HCA Houston Healthcare Medical Center successfully completed a robotic-assisted coronary angioplasty, according to InnovationMap. The technology allows doctors to perform the procedure inside a radiation-protected cockpit by using a joystick to robotically place catheters, angioplasty balloons, and stents to clear a blockage and restore blood flow. Doctors say the robot-assisted surgery is safer and more precise.

Earlier this year, two other HCA Houston Healthcare hospitals also celebrated milestones. The hospitals performed their first peripheral lung biopsies using robotic-assisted technology, according to InnovationMap. The technology allows doctors to go through the lung’s natural airways, lowering the risk of complications. It also supports the early diagnosis of lung disease when used as a screening tool due to the technology’s ability to examine hard-to-reach areas.

Robotic Device for Failing Hearts

Houston-based medtech startup, CorInnova, was recently accepted into an international accelerator program, MedTech Innovator. CorInnova has created what they describe as the world’s first minimally invasive robotic cardiac-assist device that treats acute heart failure without touching the blood. The device’s ability to collapse and self-expand makes it a less invasive option compared to other devices, according to the company. Existing devices also have higher risks of side effects, including elevated risk of stroke, blood damage and kidney problems.

According to MedTech Innovator, their accelerator programs aim to promote the growth of early and mid-stage startups by working closely with stakeholders across the industry.  

CorInnova has previously been a part of accelerator programs at TMC Innovation and is currently a resident at JLABS @ TMC. JLABS provides startups access to a medical device prototype lab and highly specialized tools to further advance their innovations. 

Houston has more than 1,900 life sciences companies, cutting edge hospitals, health facilities and research institutions with a workforce of more than 370,000 people in health care, biotech and related fields in the area. The city ranks No. 13 in CBRE’s latest analysis of the nation’s top 25 life sciences markets.

Learn more about Houston’s life sciences and biotech sectors and how the city is advancing life sciences with several large-scale development projects.

Related News

Health Care

University of Houston, Baylor College of Medicine to Launch Cutting-Edge Research Hub

8/26/24
The University of Houston (UH) and Baylor College of Medicine (BCM) have been awarded a $44.2 million grant from the National Center for Advancing Translational Research. This funding will support the establishment of a regional hub dedicated to advancing clinical and translational research.  Dubbed the Consortium for Translational and Precision Health (CTPH), the new hub will enhance collaboration between the two institutions and other clinical and research groups within the Texas Medical Center. The CTPH aims to expedite the translation of new technologies and discoveries into patient care and real-world impact, provide funding and resources to accelerate pilot projects and research initiatives and connect investigators with local healthcare organizations and government agencies that are dedicated to healthcare, clinical research and policy.  “Research is the engine empowering health care’s life-changing advancements,” said UH President Renu Khator, in a release. “This innovative hub will be a catalyst for groundbreaking discoveries and treatments that improve people’s quality of life. That’s what drives us at UH and we’re ecstatic to cofound a regional hub for change alongside Baylor.”  The hub will be led by BCM’s Christopher Amos, professor and director of the Institute for Clinical and Translational Research, and Dr. Fasiha Kanwal, professor of medicine and chief of the section of gastroenterology and hepatology, alongside UH’s Dr. Bettina M. Beech, clinical professor of population health and chief population health officer.  “The CTPH is a partnership that draws on strengths of both institutions, creating a rich multidisciplinary environment. It will act as the vehicle to enhance the infrastructure and resources needed to effectively conduct research and implement solutions to advance healthcare,” said Dr. Carolyn Smith, interim senior vice president and dean of research at BCM. “It will help implement and create ongoing core research activities that will support the clinical translational science at both institutions.”  This strategic partnership comes at a time when local institutions are intensifying efforts to advance critical research that will deliver vital healthcare solutions. The University of Texas MD Anderson Cancer Center and Rice University recently announced a collaboration to advance fundamental and translational cancer research and develop life-saving technologies. Additionally, a research initiative led by Rice University, in collaboration with MD Anderson, received an $18 million grant to improve tumor removal technology for breast, head and neck cancer.  Learn more about Houston’s Life Sciences industry. 
Read More
Life Sciences

Rice University Awarded $18 Million to Advance Tumor Removal Technology

8/16/24
A research initiative led by Rice University, in collaboration with The University of Texas MD Anderson, has received an $18 million grant from the Advanced Research Projects Agency for Health (ARPA-H). The funding, which will be distributed over five years, will support the development of a new system aimed at enhancing the accuracy of tumor removal in breast, and head and neck cancer.   Rice University was among eight institutions chosen to receive a share of the $150 million in grants announced earlier this week by the Biden-Harris administration. This funding is part of the ongoing Cancer Moonshot initiative, which seeks to halve the cancer death rate by 2047.   The Rice and MD Anderson research team has developed a groundbreaking cancer pathology system called AccessPath, which addresses a significant challenge surgeons face: accurately identifying the margin where a tumor ends, and healthy tissue begins. Leveraging advanced technologies, including a high-resolution microscope and advanced artificial intelligence algorithms, AccessPath enables surgeons to determine in real time whether they have completely removed a tumor during surgery.  “Because of its low cost, high speed, and automated analysis, we believe AccessPath can revolutionize real-time surgical guidance, greatly expanding the range of hospitals able to provide accurate intraoperative tumor margin assessment and improving outcomes for all cancer surgery patients,” Rebecca Richards-Kortum, a lead researcher on the project and director of the Rice360 Institute for Global Health Technologies, said in a news release.  According to ARPA-H, nearly two million Americans are diagnosed with cancer each year. Given the complexity and high cost of cancer treatment, AccessPath offers a promising solution by “reducing the number of repeat interventions, lowering cancer care costs and improving patient outcomes,” said Dr. Ana Paula Refinetti, an associate professor in the Breast Surgical Oncology department at MD Anderson and one of the lead researchers on the project.  This cutting-edge innovation stems from a strategic partnership established this summer between Rice University and MD Anderson. Through the Cancer Bioengineering Collaborative, the two institutions are working together to develop life-saving technologies and bioengineering strategies to enhance cancer research, diagnosis and treatment.  “AccessPath is exactly the kind of life-changing research and health care innovation we are proud to produce at Rice, where we’re committed to addressing and solving the world’s most pressing medical issues,” said Ramamoorthy Ramesh, Rice’s executive vice president for research. “Partnering with MD Anderson on this vital work underscores the importance of such ongoing collaborations with our neighbors in the world’s largest medical center.”  This award is yet another example showcasing Houston’s leadership in advancing critical, life-saving technologies.  Learn more about Houston’s life sciences industry. 
Read More

Related Events

Economic Development

Life Sciences and Biotechnology Forum

Finding solutions to the problems that matter most is baked into Houston’s DNA. As the Third Coast for Life Sciences, the region’s world-class medical centers, research institutes and private companies are taking on…

Learn More
Learn More
Executive Partners